Plain-English translation of NCT06590246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called C-CAR031 for people with advanced or recurrent liver cancer (hepatocellular carcinoma). C-CAR031 is a type of living cell therapy created from your own immune cells and designed to find and attack cancer cells. The trial will first test different doses to find the safest and most effective amount, then study how well it works in more patients.
Many people with advanced liver cancer do not respond well to current treatments like chemotherapy and targeted drugs. This medication offers a new approach by using your own immune system to fight the cancer, and researchers want to see if it can help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
The trial has two main phases. In the first phase, small groups of patients will receive the treatment at different dose levels to find the safest dose; in the second phase, more patients will receive the confirmed best dose. You will have your own immune cells collected through a special blood process, sent to a lab to be grown and modified, and then returned to you as an infusion through an IV. You will have regular clinic visits and blood tests to monitor your health, tumor response, and any side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China